Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | PDK2 | Q15119 | 2/20 | 0.35 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.35 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.35 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | GRN | P28799 | 1/20 | 0.34 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | VNN1 | O95497 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | DHX9 | Q08211 | 1/20 | 0.32 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.31 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.31 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2387266 | 0.74 | SMN1; SMN2 (0.42) | LMNAALDH1A1PDK2MKNK1MKNK2 | |
| SCHEMBL2408801 | 0.74 | ALDH1A1 (0.35) | ALDH1A1SMN1; SMN2 | |
| SCHEMBL20812218 | 0.72 | PDK2 (0.44) | LMNAALDH1A1PDK2MKNK1MKNK2 | |
| SCHEMBL369320 | 0.69 | MLYCD (0.43) | LMNAALDH1A1PDK2MKNK1MKNK2 | |
| SCHEMBL2386315 | 0.69 | L3MBTL1 (0.44) | LMNAALDH1A1PDK2SMN1; SMN2GRN | |
| SCHEMBL28147463 | 0.66 | VNN1 (0.49) | LMNAALDH1A1MKNK1MKNK2CHEK1 | |
| SCHEMBL2385414 | 0.66 | SMN1; SMN2 (0.42) | LMNAALDH1A1PDK2SMN1; SMN2GRN | |
| SCHEMBL248730 | 0.65 | — | — | |
| SCHEMBL334868 | 0.65 | — | — | |
| SCHEMBL2386141 | 0.64 | NAMPT (0.45) | LMNASMN1; SMN2GRNSORT1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8022061-B2 | 5-(Methoxymethyl)-1-(5-methyl-4-(thiophen-2-yl)pyrimidin-2-yl)-N-(pyridin-4-ylmethyl)-1H-pyrazole-4-carboxamide; for the treatment or prevention of type 2 diabetes and type 2 diabetes-related conditions | AMGEN INC. (US) | 2011-09-20 | — | — | US | disclosed |
| US-20080153778-A1 | N-aryl pyrazole compounds, compositions, and methods for their use | AMGEN INC. | 2008-06-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080153778-A1 | N-aryl pyrazole compounds, compositions, and methods for their use | GLP1R, GPR119, NAT1 | LMNA 813/4885ALDH1A1 636/4885PDK2 37/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.